Search clinical trials for: Everolimus (Afinitor) tablets

Total 7493 results

Exelixis

Completed

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

Renal Cell Carcinoma

United States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
Guangdong Provincial People's Hospital
Novartis

Unknown

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Neuroendocrine Tumors | Carcinoid Tumor

China
Queen Mary University of London
AstraZeneca; Cancer Research UK

Terminated

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer (ZEBRA)

Metastatic Clear Cell Renal Carcinoma

United Kingdom
NYU Langone Health
Novartis Pharmaceuticals; The Children's Tumor Foundation

Completed

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Neurofibromatosis Type II

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (TRACER)

Hepatocellular Carcinoma

Hong Kong, Taiwan, Thailand
German Breast Group
Novartis

Terminated

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane (Evelyn)

Metastatic Breast Cancer

Germany
Novartis Pharmaceuticals

No longer available

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Advanced Hormone Receptor Positive (HR+) Breast Cancer
Yonsei University

Completed

A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Epilepsy and Focal Cortical Dysplasia II

Korea, Republic of
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Neuroendocrine Tumors

Germany
Hopital Foch

Completed

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (AFINIVEST)

Urothelial Cancer

France
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center; Massachusetts General Hospital; Novartis; MOUNT SINAI...

Completed

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Thyroid Cancer

United States
Linda C. Higgins
University of Texas Southwestern Medical Center

Terminated

Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Kidney Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Erasmus Medical Center

Withdrawn

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome (EVAMP)

Neoplasm Metastasis | Neoplastic Processes | Peutz-Jeghers Syndrome

Netherlands
howard safran
The Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode Island; Roger...

Terminated

RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer

Head and Neck Cancer

United States
St. Joseph's Healthcare Hamilton
Novartis Pharmaceuticals; McMaster University

Completed

Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers

Carcinoma, Renal Cell

Canada
Dana-Farber Cancer Institute
Novartis Pharmaceuticals

Completed

Everolimus for Cancer With TSC1 or TSC2 Mutation

Tuberous Sclerosis Complex | TSC1 | TSC2 | MTOR

United States
Swiss Group for Clinical Cancer Research

Completed

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy

Colorectal Cancer

United States
University of Utah
Novartis

Terminated

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

Peutz-Jeghers Syndrome

United States
Centre Leon Berard

Suspended

A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (CHONRAD)

Chondrosarcoma

France
Grupo Espanol de Tumores Neuroendocrinos
Novartis Pharmaceuticals; European Neuroendocrine Tumor Society; Kantar Health

Completed

Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) (SEQTOR)

Neuroendocrine Tumors

Spain, United Kingdom, Denmark, France, Netherlands, Germany, Italy, Sweden
Masonic Cancer Center, University of Minnesota

Withdrawn

Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

Breast Cancer

United States
Mario Negri Institute for Pharmacological Research

Terminated

Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) (ORCHIDEE)

Renal Cell Carcinoma

Italy
iOMEDICO AG
Novartis

Completed

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) (MARC-2)

Metastatic Renal Cell Carcinoma | Failure of Exactly One Prior VEGF-targeted Therapy

Germany
Hannover Medical School
Novartis

Completed

Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer (RADIT)

Testicular Cancer | Germ Cell Cancer

Germany
Calithera Biosciences, Inc

Completed

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (ENTRATA)

Clear Cell Renal Cell Carcinoma

United States
Radboud University Medical Center

Completed

Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) (SPOT)

Renal Cell Carcinoma | Breast Cancer

Netherlands
National Cancer Institute, Slovakia

Completed

Everolimus in Refractory Testicular Germ Cell Cancer

Germ Cell Tumor

Slovakia
Washington University School of Medicine
Tyrogenex

Terminated

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Adenocarcinoma | Pancreatic Neoplasms

United States
Armando Santoro, MD

Completed

Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy (ONC-2010-001)

Thymoma and Thymic Carcinoma

Italy
Association Pour La Recherche des Thérapeutiques...

Completed

Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus (NEORAD)

Clear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal Carcinoma

France
Baylor College of Medicine
Novartis Pharmaceuticals

Withdrawn

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Sturge Weber Syndrome

United States
Jenny C. Chang, MD
The Methodist Hospital Research Institute

Completed

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (NECTAR)

Breast Cancer | Triple Negative Breast Cancer

United States
Hellenic Cooperative Oncology Group
Novartis

Terminated

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Gastrointestinal Tumors | Pancreatic Neuroendocrine Tumors | Pancreatic Tumors | Gastrointestinal Neuroendocrine Tumors

Greece
Sidnei Epelman

Unknown

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma

Refractory or Relapsed Osteosarcoma

Brazil
Sidnei Epelman

Unknown

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

Refractory or Relapsed RMS and Soft Tissue Sarcomas

Brazil
Shandong Suncadia Medicine Co., Ltd.

Enrolling by invitation

A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults

Metastatic or Local Advanced Breast Cancer of Patients

China
University of Cologne
Boehringer Ingelheim

Completed

BIBF 1120 and RAD001 in Solid Tumors - Phase I (BARIS)

Solid Tumors

Germany
Boston Children's Hospital
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Renal Angiomyolipoma

China
Washington University School of Medicine

Completed

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Solid Tumor | Solid Malignancy

United States
Children's Hospital Medical Center, Cincinnati
Novartis

Completed

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

Glioblastoma | Malignant Glioma of Brain | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Brainstem Glioma | Bithalamic High Grade Glioma

United States
Mustafa Sahin
Novartis Pharmaceuticals; Autism Speaks; Tuberous Sclerosis Alliance; Seizure Tracker...

Completed

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) (TSC)

Tuberous Sclerosis Complex

United States
National Institute on Drug Dependence, China
Peking University; Shengjing Hospital

Recruiting

Adjunctive Everolimus Treatment of Refractory Epilepsy

Epilepsy

China
Emory University
Novartis Pharmaceuticals

Completed

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Lung Cancer | Solid Tumors

United States
Adam Lerner
Novartis

Terminated

Everolimus in Treating Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-Cell Lymphoma

United States
Azienda Ospedaliera di Padova

Unknown

Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study (EPOCAL)

Liver Diseases | Liver Failure | Liver Cirrhosis | Liver Neoplasms

Italy
SoVarGen Co., Ltd.

Completed

Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

Pharmacokinetics

Korea, Republic of

Search clinical trials for: Everolimus (Afinitor) tablets

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations